AKREOS POSTERIOR CHAMBER INTRAOCULAR LENS,MODEL ADAPT
Bausch + Lomb, Inc. · Decision date Sep 5, 2008
What did the FDA approve?
FDA approved PMA P060022 on September 5, 2008, for the Akreos Posterior Chamber Intraocular Lens, Model Adapt, specifically the Akreos Advanced Optics Aspheric Lens, AO60. The approval covers primary implantation for visual correction of aphakia in adults after cataract removal by phacoemulsification, with placement in the capsular bag.
The source statement does not identify a supplement type or reason, so no relationship to a prior PMA scope change is established. The statement reports the device's intended purpose but does not provide independent evidence of safety or clinical effectiveness.
FDA approval order statement
APPROVAL FOR THE AKREOS POSTERIOR CHAMBER INTRAOCULAR LENS (IOL), MODEL: AKREOS ADVANCED OPTICS ASPHERIC LENS, AO60. THE DEVICE IS INDICATED FOR PRIMARY IMPLANTATION FOR THE VISUAL CORRECTION OF APHAKIA IN ADULT PATIENTS WHERE A CATARACTOUS LENS HAS BEEN REMOVED BY PHACOEMULSIFI-CATION. THE LENS IS INTENDED TO BE PLACED IN THE CAPSULAR BAG.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Ophthalmic
- Decision date
- Sep 5, 2008
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P060022
- Regulatory pathway
- Premarket approval application
- Applicant
- Bausch + Lomb, Inc.
- Product code
- HQL
- Decision code
- APPR
- Decision date
- Sep 5, 2008
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: intraocular lens.
- Applicant
- Bausch + Lomb, Inc.
- Product code
- HQL
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P060022 received
Application receipt date recorded by FDA.
P060022 · FDA decision
APPR
P060022/S038 · Related supplement
Akreos posterior chamber intraocular lens
Timeline entries are records held by MedtechLedger for P060022. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P060022
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Akreos posterior chamber intraocular lensP060022/S038 | Bausch + Lomb, Inc. | PMA supplement | Sep 3, 2026 | FDA |
Explore the linked device profile
Other records with product code HQL
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
FINEVISION HP Trifocal IOLsP240038/S004 | Beaver-Visitec International, Inc. | PMA supplement | Oct 27, 2026 | FDA |
CT LUCIA Intraocular Lenses (IOLs)P100016/S028 | Carl Zeiss Meditec Production, LLC | PMA supplement | Oct 23, 2026 | FDA |
enVista Hydrophobic Acrylic Intraocular LensP910056/S067 | Bausch + Lomb, Inc. | PMA supplement | Oct 23, 2026 | FDA |
| Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA | |
| Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 19, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Bausch + Lomb, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 50 Technology Dr., Irvine, CA, 92618
Sources and methodology
- Original FDA record: P060022
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




